News und Analysen
![EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
![EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
![Sonova further extends offering of Sennheiser-branded
hearing solutions with All-Day Clear](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
![Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
![Financial year 2022/23: Sonova delivers solid results
and preserves profit growth](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Financial year 2022/23: Sonova delivers solid results and preserves profit growth
![EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
![EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
![EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
![Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
![EQS-Adhoc: BB Biotech AG publishes its 2022 annual report](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
![EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
![EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
![Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
![Cancellation of remaining publicly held registered shares of Vifor Pharma AG: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
![EQS-News: BB BIOTECH AG: Molecular strike force for the immune system](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
![Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
![Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that
![First half results 2022/23:
Growth in all regions and further progress on strategic initiatives](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
First half results 2022/23: Growth in all regions and further progress on strategic initiatives
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
![EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
![Approval of extension of exemptions from SIX disclosure and publicity obligations: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Approval of extension of exemptions from SIX disclosure and publicity obligations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an
![Approval of delisting of Vifor Pharma AG's registered shares: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
![Sonova Investor & Analyst Day 2022:
Leading innovation and further expanding our reach](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)